XXXX in the treatment of @entity613 . Results of a randomized, double-blind, multicentre, placebo-controlled study.

@entity1 @entity2175 @entity2002 @entity6 @entity613 @entity40204 @entity158 @entity432 @entity597
AIMS: @entity1 with peripheral @entity432 require treatment to prevent major cardiovascular events and to relieve @entity613 . The walking performance of peripheral @entity432 @entity1 was used to evaluate the usefulness of @entity40204 , a glycosaminoglycan containing fast moving heparin and dermatan @entity597 . METHODS AND RESULTS: A randomized, multicentre, double-blind, placebo-controlled study was performed in 286 @entity1 with Leriche-Fontaine stage II peripheral @entity432 . @entity1 received placebo (n=143) or @entity40204 (n=143) for 27 weeks. The primary end-point was the doubling of the @entity158 -free walking distance at the end of treatment, and this was achieved by 23.8% of @entity1 treated with @entity40204 and 9.1% of those on placebo (P=0.001). The @entity158 -free walking distance increased on average (+/-SE) by 83.2+/-8.6 m (+64.7% from baseline) with @entity40204 and 36.7+/-6.2 m (+29.9% from baseline) with placebo (P=0.001). The maximum walking distance increased by 142.3+/-15.8 m (+76.0% from baseline) and 54.5+/-8.4 m (+27.9% from baseline) (P<0.001), respectively. Results for @entity1 with @entity2175 were similar to those for non- @entity6 @entity1 . Plasma @entity2002 decreased with @entity40204 , but increased with placebo. CONCLUSION: @entity40204 improved the walking ability of peripheral @entity432 @entity1 to a significantly greater extent than placebo, with a concurrent significant decrease in @entity2002 . The treatment was well tolerated.
